Abstract

For the first time, a vaccine against the avian influenza strain H5N1 has shown promise at low doses, making it a possible candidate for use in a pandemic. In a statement issued last week, GlaxoSmithKline (GSK) said that a trial involving 400 healthy volunteers in Belgium revealed that two vaccine

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.